Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e477-84. doi: 10.1016/j.ijrobp.2011.07.012. Epub 2011 Dec 15.
To perform a dosimetric comparison of intensity-modulated radiotherapy (IMRT), passive scattering proton therapy (PSPT), and intensity-modulated proton therapy (IMPT) to the para-aortic (PA) nodal region in women with locally advanced gynecologic malignancies.
The CT treatment planning scans of 10 consecutive patients treated with IMRT to the pelvis and PA nodes were identified. The clinical target volume was defined by the primary tumor for patients with cervical cancer and by the vagina and paravaginal tissues for patients with endometrial cancer, in addition to the regional lymph nodes. The IMRT, PSPT, and IMPT plans were generated using the Eclipse Treatment Planning System and were analyzed for various dosimetric endpoints. Two groups of treatment plans including proton radiotherapy were created: IMRT to pelvic nodes with PSPT to PA nodes (PSPT/IMRT), and IMRT to pelvic nodes with IMPT to PA nodes (IMPT/IMRT). The IMRT and proton RT plans were optimized to deliver 50.4 Gy or Gy (relative biologic effectiveness [RBE)), respectively. Dose-volume histograms were analyzed for all of the organs at risk. The paired t test was used for all statistical comparison.
The small-bowel V(20), V(30), V(35), andV(40) were reduced in PSPT/IMRT by 11%, 18%, 27%, and 43%, respectively (p < 0.01). Treatment with IMPT/IMRT demonstrated a 32% decrease in the small-bowel V(20). Treatment with PSPT/IMRT showed statistically significant reductions in the body V(5-20); IMPT/IMRT showed reductions in the body V(5-15). The dose received by half of both kidneys was reduced by PSPT/IMRT and by IMPT/IMRT. All plans maintained excellent coverage of the planning target volume.
Compared with IMRT alone, PSPT/IMRT and IMPT/IMRT had a statistically significant decrease in dose to the small and large bowel and kidneys, while maintaining excellent planning target volume coverage. Further studies should be done to correlate the clinical significance of these findings.
对局部晚期妇科恶性肿瘤患者的腹主动脉(PA)淋巴结区进行调强放疗(IMRT)、被动散射质子治疗(PSPT)和调强质子治疗(IMPT)的剂量学比较。
确定了 10 例连续接受骨盆和 PA 淋巴结 IMRT 治疗的患者的 CT 治疗计划扫描。宫颈癌患者的临床靶区定义为原发肿瘤,子宫内膜癌患者的临床靶区定义为阴道和阴道旁组织,以及区域淋巴结。Eclipse 治疗计划系统生成了 IMRT、PSPT 和 IMPT 计划,并对各种剂量学终点进行了分析。创建了两组质子放射治疗计划:PSPT 联合 IMRT 治疗盆腔淋巴结(PSPT/IMRT)和 IMPT 联合 IMRT 治疗盆腔淋巴结(IMPT/IMRT)。IMRT 和质子 RT 计划分别优化以提供 50.4 Gy 或 Gy(相对生物效应[RBE])。对所有危及器官进行剂量体积直方图分析。所有统计比较均采用配对 t 检验。
PSPT/IMRT 使小肠 V(20)、V(30)、V(35)和 V(40)分别减少 11%、18%、27%和 43%(p<0.01)。IMPT/IMRT 治疗使小肠 V(20)减少 32%。PSPT/IMRT 治疗使体部 V(5-20)有统计学意义的降低;IMPT/IMRT 显示体部 V(5-15)减少。PSPT/IMRT 和 IMPT/IMRT 降低了半肾受照剂量。所有计划均能很好地覆盖计划靶区。
与单独 IMRT 相比,PSPT/IMRT 和 IMPT/IMRT 使小肠和大肠以及肾脏的剂量有统计学意义的降低,同时保持了极好的计划靶区覆盖。应进一步研究这些发现的临床意义。